Android app Apple app link

Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT

By Yahoo! Finance   |   1 month ago
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a promising stock under $5 with high potential. Analysts offer mixed ratings based on the safety profile and efficacy of CX-2051, a drug for colorectal cancer.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.